Five New Collaborative Projects Will Advance Understanding of Genetic Factors that Influence the Safety and Effectiveness of Medicines
AnnouncementNovember 10, 2008
In April 2008, leaders at the National Institutes of Health (NIH) and the Center for Genomic Medicine in Japan formed the Global Alliance for Pharmacogenomics. Now scientists from the two groups have agreed to five new collaborative projects.
The new projects take advantage of ongoing studies by the NIH Pharmacogenetics Research Network (PGRN, /Research/FeaturedPrograms/PGRN/) and their collaborators, along with the Center for Genomic Medicine (CGM, http://www.src.riken.jp/english/ ) at the RIKEN institute in Japan.
Scientists in the PGRN will combine their knowledge of drug responses with the CGM’s scientific expertise in high-throughput genomic technologies. The long-term goal of the collaboration is to understand how genes affect individual responses to medicines so that doctors are better able to tailor treatments to each patient. The agencies supporting the research, NIH and RIKEN, are committed to returning the research results to society.
All of the Global Alliance for Pharmacogenomics projects are currently genome-wide association studies, which analyze and compare the sequences of thousands of genes simultaneously. As with the original five projects (see /News/Results/pages/GAP-JAPAN04142008.aspx), the five new projects, which are described below, aim to identify genetic factors associated with different responses to medicines.
More information about the Global Alliance for Pharmacogenomics, including a news release about its launch, the letter of intent that created it, and a list of research centers and investigators that provide DNA samples for its studies is available at /Research/FeaturedPrograms/PGRN/GAP/.
This page last reviewed on
8/9/2018 5:45 PM
Connect With Us: